Jericho Sciences is developing novel antiviral therapeutics and corresponding personalized diagnostics which specifically address the limitations of current combination anti-retroviral therapy (cART) in the clinical management of HIV-1 infection.
Jericho Sciences, LLC is focused on research and development of novel antiviral therapeutic and diagnostic products in areas of high medical need. The lead candidate compound exerts action via a viral peptide motif shared by many types of viruses, including human immunodeficiency virus (HIV-1). While current combination antiretroviral therapy (cART) regimens can minimize disease progression by reducing viral loads in patients, they do not address challenges posed by persistent viral reservoirs, therapeutically elusive physiological compartments and the development of drug resistance. Potential therapeutic agents useful to reduce persistent and elusive virus represents the next evolution for HIV treatment. Jericho Sciences collaborates with academic, government and industrial researchers and maintains a strong IP position for all portfolio projects.